既往使用或未使用双膦酸盐患者停用地舒单抗后血清CTX水平的回顾性评估
回顾性观察37例(33女4男,50-84岁)停用地舒单抗后7-24个月血清CTX水平,按注射次数和既往双膦酸盐暴露分组。仅1次注射者8例中7例既往用双膦酸盐,均未超绝经前范围;多次注射且既往用双膦酸盐者17例中14例CTX仍在绝经前范围;多次注射且未用双膦酸盐者12例平均CTX超绝经前上限(平均+114%,范围28-320%,p=0.003-0.005 vs 既往双膦酸盐组)。结论:多次注射后停用地舒单抗所致CTX升高可能被既往双膦酸盐暴露所预防。
要点
- 仅1次地舒单抗注射后停药者8例中7例既往用双膦酸盐,均无CTX超绝经前范围。
- 多次注射后停药且既往用双膦酸盐者17例中14例CTX仍在绝经前范围。
- 多次注射后停药且未用双膦酸盐者12例平均CTX超绝经前上限(平均+114%,p=0.003-0.005)。
核心结论
- 多次注射地舒单抗后停药出现的较高CTX水平可能被既往双膦酸盐暴露所预防。
- 该观察可能与双膦酸盐对骨的持续效应有关,当RANK配体不再被拮抗时,这种效应可阻止新形成破骨细胞的骨吸收活性。
研究设计与样本
- 回顾性观察研究,评估37例(33女4男,年龄50至84岁)停用地舒单抗后7至24个月血清CTX水平。
- 按地舒单抗注射次数(1次或多次)及既往双膦酸盐暴露情况分析CTX水平。
主要发现
- 仅接受1次地舒单抗注射的8例患者中,7例既往使用双膦酸盐,停药后无一例CTX超过绝经前范围。
- 多次注射(4.1±1.4次,范围2-7次)后停药且既往暴露双膦酸盐(平均暴露6.9±5.8年,范围11个月至15年;距地舒单抗启动平均25±10个月,范围0-48个月)的17例中,14例CTX仍在绝经前范围。
- 多次注射(5次,范围3-9次)后停药且未暴露双膦酸盐的12例,末次注射后平均11.3个月(范围6-23个月)测得的平均CTX水平超过绝经前范围上限(平均+114%,范围28-320%,p=0.003-0.005 vs 既往双膦酸盐组)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Discontinuation of denosumab (Dmab) therapy is associated with lower serum CTX levels in osteoporotic patients previously exposed to bisphosphonates compared to those who were not. INTRODUCTION: Discontinuation of Dmab therapy is followed by a transient increase of bone turnover markers (BTMs) above pretreatment values, together with accelerated bone loss, and potentially an increased risk of multiple vertebral fractures. Since a substantial proportion of patients discontinuing Dmab have previously been exposed to bisphosphonates (BPs), we hypothesized that previous BP therapy could attenuate this increase in bone turnover because of the prolonged biological effects of BPs on bone. METHODS: In a retrospective observation, we assessed serum CTX levels between 7 and 24 months after the last Dmab injection in 37 patients (33 women and 4 men, aged 50 to 84 years). CTX levels were analyzed according to the number of Dmab injections (1 or multiple) and previous exposure to BPs. RESULTS: In 8 patients who had received only 1 Dmab injection, 7 out of 8 were previously on BPs and none of them showed CTX values above the premenopausal range after Dmab discontinuation. CTX also remained in the premenopausal range in 14 out of 17 patients who discontinued Dmab after multiple (4.1 ± 1.4, range 2-7) injections but were previously exposed to BPs (mean exposure 6.9 ± 5.8 years, range 11 months-15 years; mean time interval between BP exposure and Dmab initiation 25 ± 10 months, range 0-48). In contrast, in 12 patients who discontinued Dmab after multiple (5, range 3-9) injections without prior exposure to BPs, mean CTX levels as measured on average 11.3 months (range 6-23) after the last Dmab injection were above the upper limit of premenopausal range (mean +114%, range 28-320%, p = 0.003-0.005 vs previous BPs). CONCLUSION: The higher CTX levels occurring after Dmab discontinuation in patients who have received multiple injections may be prevented by prior exposure to BPs. This observation may be related to the persistent effects of BPs on bone that prevent the resorbing activity of newly formed osteoclasts when RANK Ligand is no more antagonized.
引用
- Uebelhart B, Rizzoli R, Ferrari SL, et al. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates. Osteoporos Int. 2017. PMID: 28540505. doi:10.1007/s00198-017-4080-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。